Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L Frandsen; Jonas Abrahamsson; Birgitte Lausen; Kim Vettenranta; Mats Heyman; Michael Behrentz; Anders Castor; Peder Skov Wehner; Britt-marie Frost; Louise Elisabeth Andersen; Kjeld Schmiegelow

doi:10.1111/j.1365-2141.2011.08835.x

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L Frandsen, Jonas Abrahamsson, Birgitte Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder Skov Wehner, Britt-marie Frost, Louise Elisabeth Andersen, Kjeld Schmiegelow

9 Citations (Scopus)

Abstract

This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

Original language	English
Journal	British Journal of Haematology
Volume	155
Issue number	2
Pages (from-to)	244-7
Number of pages	4
ISSN	0007-1048
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08835.x
Publication status	Published - Oct 2011

Access to Document

10.1111/j.1365-2141.2011.08835.x

Fingerprint

Dive into the research topics of 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study'. Together they form a unique fingerprint.

Cite this

Frandsen, T. L., Abrahamsson, J., Lausen, B., Vettenranta, K., Heyman, M., Behrentz, M., Castor, A., Wehner, P. S., Frost, B., Andersen, L. E., & Schmiegelow, K. (2011). Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology, 155(2), 244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. / Frandsen, Thomas L; Abrahamsson, Jonas; Lausen, Birgitte et al.

In: British Journal of Haematology, Vol. 155, No. 2, 10.2011, p. 244-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Frandsen, TL, Abrahamsson, J, Lausen, B, Vettenranta, K, Heyman, M, Behrentz, M, Castor, A, Wehner, PS, Frost, B, Andersen, LE & Schmiegelow, K 2011, 'Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study', British Journal of Haematology, vol. 155, no. 2, pp. 244-7. https://doi.org/10.1111/j.1365-2141.2011.08835.x

Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M et al. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. British Journal of Haematology. 2011 Oct;155(2):244-7. doi: 10.1111/j.1365-2141.2011.08835.x

Frandsen, Thomas L ; Abrahamsson, Jonas ; Lausen, Birgitte et al. / Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. In: British Journal of Haematology. 2011 ; Vol. 155, No. 2. pp. 244-7.

@article{d6b3c7d52eaf4b25a3ac9199619ac4b6,

title = "Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study",

abstract = "This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.",

author = "Frandsen, {Thomas L} and Jonas Abrahamsson and Birgitte Lausen and Kim Vettenranta and Mats Heyman and Michael Behrentz and Anders Castor and Wehner, {Peder Skov} and Britt-marie Frost and Andersen, {Louise Elisabeth} and Kjeld Schmiegelow",

note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",

year = "2011",

month = oct,

doi = "10.1111/j.1365-2141.2011.08835.x",

language = "English",

volume = "155",

pages = "244--7",

journal = "British Journal of Haematology, Supplement",

issn = "0963-1860",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

AU - Frandsen, Thomas L

AU - Abrahamsson, Jonas

AU - Lausen, Birgitte

AU - Vettenranta, Kim

AU - Heyman, Mats

AU - Behrentz, Michael

AU - Castor, Anders

AU - Wehner, Peder Skov

AU - Frost, Britt-marie

AU - Andersen, Louise Elisabeth

AU - Schmiegelow, Kjeld

PY - 2011/10

Y1 - 2011/10

N2 - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

AB - This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

U2 - 10.1111/j.1365-2141.2011.08835.x

DO - 10.1111/j.1365-2141.2011.08835.x

M3 - Journal article

SN - 0963-1860

VL - 155

SP - 244

EP - 247

JO - British Journal of Haematology, Supplement

JF - British Journal of Haematology, Supplement

IS - 2

ER -